Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores)

被引：6
作者：
Branco C.C. [1 ,2 ]
Pereirinha T. [1 ]
Cabral R. [1 ,2 ]
Pacheco P.R. [1 ,2 ]
Mota-Vieira L. [1 ,2 ]
机构：
[1] Molecular Genetics and Pathology Unit, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, São Miguel Island, Azores
[2] Instituto Gulbenkian de Ciência, Oeiras
来源：
Thrombosis Journal | / 7卷 / 1期
关键词：
Warfarin; Warfarin Dose; Warfarin Dose Requirement; Warfarin Maintenance Dose; Thrombotic Risk Factor;
D O I：
10.1186/1477-9560-7-9
中图分类号：
学科分类号：
摘要：
Background: The Azorean population presents the highest standardized mortality rate for cardiovascular diseases (CVD) when compared to mainland Portugal and other populations. Since thrombosis is a common cause of CVD, we assessed four polymorphisms in three thrombotic risk genes - F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C), in 469 healthy blood donors from São Miguel Island (Azores). We also analysed the CYP2C9 (C430T, A1075C) and VKORC1 (G1639A) variants in fifty-eight individuals with predisposition to thrombosis (possessing at least one variation in F5 or F2 genes and one in MTHFR) to evaluate their warfarin drug response genetic profiles. Results: Among the 469 individuals, the data showed that thrombotic risk allele frequencies - 1691A (4.9%), 20210A (1.8%), 677T (41.7%) and 1298C (24.8%) - were similar to other Caucasians, but significantly different from mainland Portuguese (χ2, p < 0.001). The combined analysis of these variants identified twenty-two different genetic profiles (genotype order: F5, F2, MTHFR C677T and A1298C). Complete homozygosity for all wild-type alleles (GG GG CC AA) was present in 11.7%, being GG GG CT AA (22.4%) the most frequent profile. The results also demonstrated that 12.4% (58 out of 469) of São Miguel islanders have increased genetic predisposition to thrombosis. Subsequently, we evaluated these individuals for their warfarin response genetic profiles. The data showed that seven out of fifty-eight individuals are poor metabolizers (two with CYP2C9*2/*2 and five with CYP2C9*2/*3 genotypes). VKORC1 polymorphism analysis identified twelve individuals (20.7%) with AA genotype, who probably will require lower doses of warfarin. The joint analysis of CYP2C9 and VKORC1 revealed that 79.3% (46 out of 58) of the individuals carry at least one polymorphism in these genes. Within these, twenty-five individuals (43.1%) need intermediate and/or low doses of warfarin, if treatment is started. Conclusion: The present study demonstrated, for the first time, that São Miguel, and possibly the Azores population, shows significant differences on allele frequencies of thrombotic risk factors when compared to mainland Portugal. This research constitutes a primary approach for future studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's genotypic information. © 2009 Branco et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 46 条
  • [1] Menon J., Salman M.M., Md G.H., Venous thrombolysis: Current perspectives, Curr Treat Options Cardiovasc Med, 6, pp. 159-168, (2004)
  • [2] Cardiovascular Disease: Prevention and Control (WHO Global Strategy on Diet, Physical Activity and Health), (2008)
  • [3] Rosendaal F.R., Venous thrombosis, a multicausal disease, Lancet, 353, pp. 1167-1173, (1999)
  • [4] Khan S., Dickerman J.D., Hereditary thrombophilia, Thromb J, 4, pp. 1-17, (2006)
  • [5] Bertina R.M., Reitsma R.H., Rosendaal F.R., Vandenbroucke J.P., Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis, Thromb Haemost, 74, pp. 449-553, (1995)
  • [6] Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M., A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, 88, pp. 3698-3703, (1996)
  • [7] Varga E.A., Sturm A.C., Misita C.P., Moll S., Homocysteine and MTHFR mutations. Relation to thrombosis and coronary artery disease, Circulation, 111, (2005)
  • [8] Almawi W.Y., Ameen G., Tamim H., Finan R.R., Irani-Hakime N., Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphisms in angiographically documented coronary artery disease, J Thromb Thrombolysis, 17, pp. 199-205, (2004)
  • [9] Den Heijer M., Lewington S., Clarke R., Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies, J Thromb Haemost, 3, pp. 292-299, (2005)
  • [10] Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Shouten E.G., MTHFR 677C>T polymorphism and risk of coronary heart disease. A meta-analysis, JAMA, 288, pp. 2023-2031, (2002)
12345